Anwesha Kar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anwesha Kar has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Puspendu Ghosh
Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India
22 shared publications - Anupam Gautam
Institute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany
21 shared publications - Sandip Paul
Centre for Health Science and Technology, JIS Institute of Advanced Studies and Research Kolkata, JIS University, Kolkata, India
21 shared publications - Shilpak Chatterjee
Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India
21 shared publications - Snehanshu Chowdhury
Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India
21 shared publications Debaleena Bhowmik
19 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Mettl3-Dnmt3b Axis Shapes CD8⁺ T Cell Differentiation and Anti-Tumor Immunity
The heterogeneity in patient responses to immune checkpoint blockade (ICB) therapy is largely attributed to the presence of distinct exhausted CD8⁺ T-cell subsets with differential therapeutic potentials. While progenitor exhausted (pTex) CD8⁺ T cells retain responsiveness to ICB, terminally exhausted (tTex) CD8⁺ T cells are highly refractory. However, the molecular mechanisms governing the divergent fate commitment of these subsets remain poorly understood. Here, we identify the RNA methyltransferase Mettl3 as a critical regulator of terminal differentiation in CD8⁺ T cells, functioning to suppress pTex cell generation. Across multiple murine tumor models, human samples, and adoptive transfer systems, Mettl3 expression was selectively enriched in tTex cells and inversely correlated with pTex populations. Mechanistically, Mettl3 promoted terminal exhaustion by stabilizing DNMT3B transcripts through m⁶A-dependent modification, thereby reinforcing CpG methylation and chromatin compaction at loci associated with memory and progenitor programs. This epitranscriptomic-epigenetic circuit restricted the proliferative burst capacity of T cells upon anti-PD1 therapy. Importantly, inhibition of the Mettl3-Dnmt3b axis reprogrammed chromatin accessibility toward a memory-like state, preserved progenitor potential, and enhanced effector function. Consequently, Mettl3-deficient T cells exhibited superior persistence, improved recall responses, and enhanced tumor control following anti-PD1 therapy. Collectively, our findings establish the Mettl3-Dnmt3b axis as a molecular rheostat controlling CD8⁺ T-cell fate decisions through coordinated epitranscriptomic and epigenetic regulation. This study identifies a therapeutically actionable mechanism underlying terminal T-cell dysfunction and highlights targeting the Mettl3-Dnmt3b pathway as a promising strategy to improve the durability and efficacy of ICB therapy.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMettl3-Dnmt3b Axis Shapes CD8⁺ T Cell Differentiation and Anti-Tumor Immunity
The heterogeneity in patient responses to immune checkpoint blockade (ICB) therapy is largely attributed to the presence of distinct exhausted CD8⁺ T-cell subsets with differential therapeutic potentials. While progenitor exhausted (pTex) CD8⁺ T cells retain responsiveness to ICB, terminally exhausted (tTex) CD8⁺ T cells are highly refractory. However, the molecular mechanisms governing the divergent fate commitment of these subsets remain poorly understood. Here, we identify the RNA methyltransferase Mettl3 as a critical regulator of terminal differentiation in CD8⁺ T cells, functioning to suppress pTex cell generation. Across multiple murine tumor models, human samples, and adoptive transfer systems, Mettl3 expression was selectively enriched in tTex cells and inversely correlated with pTex populations. Mechanistically, Mettl3 promoted terminal exhaustion by stabilizing DNMT3B transcripts through m⁶A-dependent modification, thereby reinforcing CpG methylation and chromatin compaction at loci associated with memory and progenitor programs. This epitranscriptomic-epigenetic circuit restricted the proliferative burst capacity of T cells upon anti-PD1 therapy. Importantly, inhibition of the Mettl3-Dnmt3b axis reprogrammed chromatin accessibility toward a memory-like state, preserved progenitor potential, and enhanced effector function. Consequently, Mettl3-deficient T cells exhibited superior persistence, improved recall responses, and enhanced tumor control following anti-PD1 therapy. Collectively, our findings establish the Mettl3-Dnmt3b axis as a molecular rheostat controlling CD8⁺ T-cell fate decisions through coordinated epitranscriptomic and epigenetic regulation. This study identifies a therapeutically actionable mechanism underlying terminal T-cell dysfunction and highlights targeting the Mettl3-Dnmt3b pathway as a promising strategy to improve the durability and efficacy of ICB therapy.
- Open Access
- 19 March 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (8) , 2000-2028
S1P-S1PR1 signaling impairs CD8+ T cell metabolism and effector function in tumors
Sphingosine-1-phosphate receptor 1 (S1PR1) signaling has been linked to the regulation of immunosuppressive cell populations within the tumor microenvironment (TME); however, its role in shaping anti-tumor CD8⁺ T cell responses remains poorly defined. Herein, we demonstrate that intratumoral CD8⁺ T cells express S1PR1, with expression predominantly enriched in the terminally exhausted subset. Transcriptomic profiling, combined with pharmacological inhibition and genetic knockdown, reveals that S1PR1-S1P signaling activates the PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase)-CHOP (C/EBP homologous protein) axis of the endoplasmic reticulum stress response. CHOP, in turn, upregulates transcription of Map3k13 and Map3k15 , triggering downstream MAPK signaling and culminating in activation of p38MAPK. Activation of this pathway impairs CD8⁺ T cell metabolism and effector function while increasing apoptotic susceptibility. This ultimately limits the persistence and accumulation of functional CD8⁺ T cells within the TME, thereby compromising their responsiveness to anti-PD-1 therapy. Targeting the S1PR1-S1P axis or its downstream effectors offers a promising strategy to improve cancer immunotherapy outcomes.
- 19 March 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (8) , 2000-2028
Open AccessS1P-S1PR1 signaling impairs CD8+ T cell metabolism and effector function in tumors
Sphingosine-1-phosphate receptor 1 (S1PR1) signaling has been linked to the regulation of immunosuppressive cell populations within the tumor microenvironment (TME); however, its role in shaping anti-tumor CD8⁺ T cell responses remains poorly defined. Herein, we demonstrate that intratumoral CD8⁺ T cells express S1PR1, with expression predominantly enriched in the terminally exhausted subset. Transcriptomic profiling, combined with pharmacological inhibition and genetic knockdown, reveals that S1PR1-S1P signaling activates the PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase)-CHOP (C/EBP homologous protein) axis of the endoplasmic reticulum stress response. CHOP, in turn, upregulates transcription of Map3k13 and Map3k15 , triggering downstream MAPK signaling and culminating in activation of p38MAPK. Activation of this pathway impairs CD8⁺ T cell metabolism and effector function while increasing apoptotic susceptibility. This ultimately limits the persistence and accumulation of functional CD8⁺ T cells within the TME, thereby compromising their responsiveness to anti-PD-1 therapy. Targeting the S1PR1-S1P axis or its downstream effectors offers a promising strategy to improve cancer immunotherapy outcomes.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary table for all up and down-regulated genes from RNAseq analysis
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary table for all up and down-regulated genes from RNAseq analysis
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 and S3 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary tables for p values
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 and S3 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary tables for p values
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary figures and figure legends
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary figures and figure legends
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Effector CD8+ T cells rely primarily on glucose metabolism to meet their biosynthetic and functional needs. However, nutritional limitations in the tumor microenvironment can cause T-cell hyporesponsiveness. Therefore, T cells must acquire metabolic traits enabling sustained effector function at the tumor site to elicit a robust antitumor immune response. Here, we report that IL12-stimulated CD8+ T cells have elevated intracellular acetyl CoA levels and can maintain IFNγ levels in nutrient-deprived, tumor-conditioned media (TCM). Pharmacological and metabolic analyses demonstrated an active glucose–citrate–acetyl CoA circuit in IL12-stimulated CD8+ T cells supporting an intracellular pool of acetyl CoA in an ATP-citrate lyase (ACLY)–dependent manner. Intracellular acetyl CoA levels enhanced histone acetylation, lipid synthesis, and IFNγ production, improving the metabolic and functional fitness of CD8+ T cells in tumors. Pharmacological inhibition or genetic knockdown of ACLY severely impaired IFNγ production and viability of CD8+ T cells in nutrient-restricted conditions. Furthermore, CD8+ T cells cultured in high pyruvate–containing media in vitro acquired critical metabolic features of IL12-stimulated CD8+ T cells and displayed improved antitumor potential upon adoptive transfer in murine lymphoma and melanoma models. Overall, this study delineates the metabolic configuration of CD8+ T cells required for stable effector function in tumors and presents an affordable approach to promote the efficacy of CD8+ T cells for adoptive T-cell therapy.Significance:IL12-mediated metabolic reprogramming increases intracellular acetyl CoA to promote the effector function of CD8+ T cells in nutrient-depleted tumor microenvironments, revealing strategies to potentiate the antitumor efficacy of T cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Effector CD8+ T cells rely primarily on glucose metabolism to meet their biosynthetic and functional needs. However, nutritional limitations in the tumor microenvironment can cause T-cell hyporesponsiveness. Therefore, T cells must acquire metabolic traits enabling sustained effector function at the tumor site to elicit a robust antitumor immune response. Here, we report that IL12-stimulated CD8+ T cells have elevated intracellular acetyl CoA levels and can maintain IFNγ levels in nutrient-deprived, tumor-conditioned media (TCM). Pharmacological and metabolic analyses demonstrated an active glucose–citrate–acetyl CoA circuit in IL12-stimulated CD8+ T cells supporting an intracellular pool of acetyl CoA in an ATP-citrate lyase (ACLY)–dependent manner. Intracellular acetyl CoA levels enhanced histone acetylation, lipid synthesis, and IFNγ production, improving the metabolic and functional fitness of CD8+ T cells in tumors. Pharmacological inhibition or genetic knockdown of ACLY severely impaired IFNγ production and viability of CD8+ T cells in nutrient-restricted conditions. Furthermore, CD8+ T cells cultured in high pyruvate–containing media in vitro acquired critical metabolic features of IL12-stimulated CD8+ T cells and displayed improved antitumor potential upon adoptive transfer in murine lymphoma and melanoma models. Overall, this study delineates the metabolic configuration of CD8+ T cells required for stable effector function in tumors and presents an affordable approach to promote the efficacy of CD8+ T cells for adoptive T-cell therapy.Significance:IL12-mediated metabolic reprogramming increases intracellular acetyl CoA to promote the effector function of CD8+ T cells in nutrient-depleted tumor microenvironments, revealing strategies to potentiate the antitumor efficacy of T cells.
- Open Access
- 7 March 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (11)
CD38–RyR2 axis–mediated signaling impedes CD8 + T cell response to anti-PD1 therapy in cancer
PD1 blockade therapy, harnessing the cytotoxic potential of CD8 + T cells, has yielded clinical success in treating malignancies. However, its efficacy is often limited due to the progressive differentiation of intratumoral CD8 + T cells into a hypofunctional state known as terminal exhaustion. Despite identifying CD8 + T cell subsets associated with immunotherapy resistance, the molecular pathway triggering the resistance remains elusive. Given the clear association of CD38 with CD8 + T cell subsets resistant to anti-PD1 therapy, we investigated its role in inducing resistance. Phenotypic and functional characterization, along with single-cell RNA sequencing analysis of both in vitro chronically stimulated and intratumoral CD8 + T cells, revealed that CD38-expressing CD8 + T cells are terminally exhausted. Exploring the molecular mechanism, we found that CD38 expression was crucial in promoting terminal differentiation of CD8 + T cells by suppressing TCF1 expression, thereby rendering them unresponsive to anti-PD1 therapy. Genetic ablation of CD38 in tumor-reactive CD8 + T cells restored TCF1 levels and improved the responsiveness to anti-PD1 therapy in mice. Mechanistically, CD38 expression on exhausted CD8 + T cells elevated intracellular Ca 2+ levels through RyR2 calcium channel activation. This, in turn, promoted chronic AKT activation, leading to TCF1 loss. Knockdown of RyR2 or inhibition of AKT in CD8 + T cells maintained TCF1 levels, induced a sustained anti-tumor response, and enhanced responsiveness to anti-PD1 therapy. Thus, targeting CD38 represents a potential strategy to improve the efficacy of anti-PD1 treatment in cancer.
- 7 March 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (11)
Open AccessCD38–RyR2 axis–mediated signaling impedes CD8 + T cell response to anti-PD1 therapy in cancer
PD1 blockade therapy, harnessing the cytotoxic potential of CD8 + T cells, has yielded clinical success in treating malignancies. However, its efficacy is often limited due to the progressive differentiation of intratumoral CD8 + T cells into a hypofunctional state known as terminal exhaustion. Despite identifying CD8 + T cell subsets associated with immunotherapy resistance, the molecular pathway triggering the resistance remains elusive. Given the clear association of CD38 with CD8 + T cell subsets resistant to anti-PD1 therapy, we investigated its role in inducing resistance. Phenotypic and functional characterization, along with single-cell RNA sequencing analysis of both in vitro chronically stimulated and intratumoral CD8 + T cells, revealed that CD38-expressing CD8 + T cells are terminally exhausted. Exploring the molecular mechanism, we found that CD38 expression was crucial in promoting terminal differentiation of CD8 + T cells by suppressing TCF1 expression, thereby rendering them unresponsive to anti-PD1 therapy. Genetic ablation of CD38 in tumor-reactive CD8 + T cells restored TCF1 levels and improved the responsiveness to anti-PD1 therapy in mice. Mechanistically, CD38 expression on exhausted CD8 + T cells elevated intracellular Ca 2+ levels through RyR2 calcium channel activation. This, in turn, promoted chronic AKT activation, leading to TCF1 loss. Knockdown of RyR2 or inhibition of AKT in CD8 + T cells maintained TCF1 levels, induced a sustained anti-tumor response, and enhanced responsiveness to anti-PD1 therapy. Thus, targeting CD38 represents a potential strategy to improve the efficacy of anti-PD1 treatment in cancer.
- Open Access
- 16 June 2023
- Published by American Association for Cancer Research (AACR)
Data from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Effector CD8+ T cells rely primarily on glucose metabolism to meet their biosynthetic and functional needs. However, nutritional limitations in the tumor microenvironment can cause T-cell hyporesponsiveness. Therefore, T cells must acquire metabolic traits enabling sustained effector function at the tumor site to elicit a robust antitumor immune response. Here, we report that IL12-stimulated CD8+ T cells have elevated intracellular acetyl CoA levels and can maintain IFNγ levels in nutrient-deprived, tumor-conditioned media (TCM). Pharmacological and metabolic analyses demonstrated an active glucose–citrate–acetyl CoA circuit in IL12-stimulated CD8+ T cells supporting an intracellular pool of acetyl CoA in an ATP-citrate lyase (ACLY)–dependent manner. Intracellular acetyl CoA levels enhanced histone acetylation, lipid synthesis, and IFNγ production, improving the metabolic and functional fitness of CD8+ T cells in tumors. Pharmacological inhibition or genetic knockdown of ACLY severely impaired IFNγ production and viability of CD8+ T cells in nutrient-restricted conditions. Furthermore, CD8+ T cells cultured in high pyruvate–containing media in vitro acquired critical metabolic features of IL12-stimulated CD8+ T cells and displayed improved antitumor potential upon adoptive transfer in murine lymphoma and melanoma models. Overall, this study delineates the metabolic configuration of CD8+ T cells required for stable effector function in tumors and presents an affordable approach to promote the efficacy of CD8+ T cells for adoptive T-cell therapy.Significance:IL12-mediated metabolic reprogramming increases intracellular acetyl CoA to promote the effector function of CD8+ T cells in nutrient-depleted tumor microenvironments, revealing strategies to potentiate the antitumor efficacy of T cells.
- 16 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Effector CD8+ T cells rely primarily on glucose metabolism to meet their biosynthetic and functional needs. However, nutritional limitations in the tumor microenvironment can cause T-cell hyporesponsiveness. Therefore, T cells must acquire metabolic traits enabling sustained effector function at the tumor site to elicit a robust antitumor immune response. Here, we report that IL12-stimulated CD8+ T cells have elevated intracellular acetyl CoA levels and can maintain IFNγ levels in nutrient-deprived, tumor-conditioned media (TCM). Pharmacological and metabolic analyses demonstrated an active glucose–citrate–acetyl CoA circuit in IL12-stimulated CD8+ T cells supporting an intracellular pool of acetyl CoA in an ATP-citrate lyase (ACLY)–dependent manner. Intracellular acetyl CoA levels enhanced histone acetylation, lipid synthesis, and IFNγ production, improving the metabolic and functional fitness of CD8+ T cells in tumors. Pharmacological inhibition or genetic knockdown of ACLY severely impaired IFNγ production and viability of CD8+ T cells in nutrient-restricted conditions. Furthermore, CD8+ T cells cultured in high pyruvate–containing media in vitro acquired critical metabolic features of IL12-stimulated CD8+ T cells and displayed improved antitumor potential upon adoptive transfer in murine lymphoma and melanoma models. Overall, this study delineates the metabolic configuration of CD8+ T cells required for stable effector function in tumors and presents an affordable approach to promote the efficacy of CD8+ T cells for adoptive T-cell therapy.Significance:IL12-mediated metabolic reprogramming increases intracellular acetyl CoA to promote the effector function of CD8+ T cells in nutrient-depleted tumor microenvironments, revealing strategies to potentiate the antitumor efficacy of T cells.
- Open Access
- 16 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary figures and figure legends
- 16 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary figures and figure legends
- Open Access
- 16 June 2023
- Published by American Association for Cancer Research (AACR)
Table S2 and S3 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary tables for p values
- 16 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 and S3 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells
Supplementary tables for p values